EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial

Inderpal S Sarkaria, Linda W Martin, David C Rice, Shanda H Blackmon, Herbert B Slade, Sunil Singhal, ELUCIDATE Study Group

The Journal of Thoracic and Cardiovascular Surgery · 2023-12 · 166 (6) · e468-e478

DOI: 10.1016/j.jtcvs.2023.02.025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2023-12. Verfasst von Inderpal S Sarkaria und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, Pa. Hauptthemen laut MEDLINE: Margins of Excision, Lung Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intuitive Surgical, On Target Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The study objective was to determine the clinical utility of pafolacianine, a folate receptor-targeted fluorescent agent, in revealing by intraoperative molecular imaging folate receptor α positive cancers in the lung and narrow surgical margins that may otherwise be undetected with conventional visualization. METHODS: In this Phase 3, 12-center trial, 112 patients with suspected or biopsy-confirmed cancer in the lung scheduled for sublobar pulmonary resection were administered intravenous pafolacianine within 24 hours before surgery. Participants were randomly assigned to surgery with or without intraoperative molecular imaging (10:1 ratio). The primary end point was the proportion of participants with a clinically significant event, reflecting a meaningful change in the surgical operation. RESULTS: No drug-related serious adverse events occurred. One or more clinically significant event occurred in 53% of evaluated participants compared with a prespecified limit of 10% (P < .0001). In 38 participants, at least 1 event was a margin 10 mm or less from the resected primary nodule (38%, 95% confidence interval, 28.5-48.3), 32 being confirmed by histopathology. In 19 subjects (19%, 95% confidence interval, 11.8-28.1), intraoperative molecular imaging located the primary nodule that the surgeon could not locate with white light and palpation. Intraoperative molecular imaging revealed 10 occult synchronous malignant lesions in 8 subjects (8%, 95% confidence interval, 3.5-15.2) undetected using white light. Most (73%) intraoperative molecular imaging-discovered synchronous malignant lesions were outside the planned resection field. A change in the overall scope of surgical procedure occurred for 29 of the subjects (22 increase, 7 decrease). CONCLUSIONS: Intraoperative molecular imaging with pafolacianine improves surgical outcomes by identifying occult tumors and close surgical margins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Margins of ExcisionLung NeoplasmsHumansLungMolecular ImagingFolic Acid

Stichwörter der Autor:innen

folate receptor alphalung cancermolecular imaging

Substanzen

PafolacianineFolic Acid

Autor:innen und Institutionen

  • University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, Pa.
  • University of Virginia Medical School, Charlottesville, Va.
  • The University of Texas MD Anderson Cancer Center, Houston, Tex.
  • Mayo Clinic College of Medicine and Science, Rochester, Minn.
  • Deptartment of Pediatrics, University of North Texas Health Science Center, Fort Worth, Tex.
  • University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa. Electronic address: Sunil.Singhal@pennmedicine.upenn.edu.

Förderung

  • NCI NIH HHS
  • Intuitive Surgical
  • On Target Laboratories
  • AstraZeneca

Zitieren

APA

Sarkaria, I. S., Martin, L. W., Rice, D. C., Blackmon, S. H., Slade, H. B., Singhal, S., & ELUCIDATE Study Group (2023). Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial. The Journal of Thoracic and Cardiovascular Surgery, 166(6), e468-e478. https://doi.org/10.1016/j.jtcvs.2023.02.025

Vancouver

Sarkaria IS, Martin LW, Rice DC, Blackmon SH, Slade HB, Singhal S, et al. Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial. The Journal of Thoracic and Cardiovascular Surgery. 2023;166(6):e468-e478. doi:10.1016/j.jtcvs.2023.02.025

BibTeX
@article{Sarkaria2023,
  author = {Sarkaria, Inderpal S and Martin, Linda W and Rice, David C and Blackmon, Shanda H and Slade, Herbert B and Singhal, Sunil and ELUCIDATE Study Group, ELUCIDATE Study Group},
  title = {Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2023},
  volume = {166},
  number = {6},
  pages = {e468--e478},
  doi = {10.1016/j.jtcvs.2023.02.025}
}
Kostenlos starten →